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ABSTRACT
Ultraviolet (UV) radiation has been applied to treat many chronic skin 
diseases. Based on the wavelength, UV radiation consists of three types, 
namely ultraviolet C (UVC), ultraviolet B (UVB), and ultraviolet A (UVA). The 
types of UV that are widely used in dermatology are narrowband ultraviolet 
B (NB-UVB), broadband ultraviolet B (BB-UVB), UVA1, and psoralen combined 
with UVA (PUVA). The interaction between UV and the skin determines the 
effectiveness of phototherapy. The biological effects of UV are used in the 
management of inflammatory skin diseases, malignancies, and various rare 
dermatoses. Apart from these benefits, UV increases the risk of photoaging 
and skin cancer. Therefore, further researches are necessary to enhance the 
effectiveness and safety of phototherapy. This literature review discusses the 
role of phototherapy in various dermatoses other than psoriasis and vitiligo.
ABSTRAK
Radiasi sinar ultraviolet (UV) telah digunakan untuk pengobatan penyakit 
kulit kronik. Berdasarkan Panjang gelombangnya, radiasi UV dibedakan 
dalam tiga jenis yaitu ultraviolet C (UVC), ultraviolet B (UVB), dan ultraviolet 
A (UVA). Jenis UV yang digunanakan secara luas dalam dematologi adalah 
narrowband ultraviolet B (NB-UVB), broadbrand ultraviolet B (BB-UVB), UVA1, 
dan psoralen dikombinasikan dengan UVA (PUVA). Interaksi antara UV dan 
kulit menentukan efektivitas fototerapi. Efek biologi UV digunakan dalam 
pengelolaan penyakit kulit inflamasi, malignansi, dan berbagai penyakit kulit 
yang jarang. Terlepas dari manfaatnya, UV meningkatkan risiko fotoaging dan 
kanker kulit. Oleh karena itu, penelitian lanjut diperlukan untuk meningkatkan 
efektivitas dan keamanan fototerapi. Kajian pustaka ini membicarakan peran 
fototerapi dalam berbagai penyakit kulit selain psoriasis dan vitiligo.
    
INTRODUCTION
Ultraviolet (UV) radiation has 
been applied to treat many chronic skin 
diseases. The International Commission 
on Radiation (CIE) classifies UV into 
three subdivisions based on their 
wavelengths, namely UVA 400-315 nm, 
UVB 315-280 nm, and UVC 280-100 nm. 
In dermatology, phototherapy with 
narrowband ultraviolet B (NB-UVB), 
broadband ultraviolet B (BB-UVB), 
ultraviolet A-1 (UVA1), and ultraviolet 
A combined with psoralen (PUVA) has 
been used extensively. Phototherapy 
units produce radiation by converting 
electrical into electromagnetic energy.1 
Phototherapy is commonly used by 
dermatologists either as a single or 
in combination with topical and/or 
systemic therapy for the management 
of inflammatory, malignancies, and 
various rare dermatoses.2 Phototherapy 
is proven effective and safe even for 
children and the elderly.3,4 This literature 
review discusses the role of phototherapy 
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in various dermatoses. The discussion is 
focused on dermatoses that are rarely 
managed, excluding psoriasis and 
vitiligo because the literature on the role 
of phototherapy in these dermatoses has 
been widely published.
A comprehensive database search 
was performed in MEDLINE, EMBASE, 
and the Cochrane library with the main 
keywords used were phototherapy, 
dermatoses, PUVA, ultraviolet, NBUVB, 
and each dermatosis discussed below. 
Selection was performed based on 
the article including randomized and 
nonrandomized clinical trials, open 
trials, and case reports or series published 
in the last 10 years (from 2010 to 2020). 
Other light base modalities such as 
excimer laser and photodynamic therapy 
were excluded from the discussion.
DISCUSSION
Biological Effects of Phototherapy
Effects of phototherapy on DNA
The direct damage of DNA is 
mediated by UVB radiation, while the 
indirect damage is caused by UVA 
exposure.5 Nucleotides in DNA absorb 
UVB to form DNA photoproducts, such 
as cyclobutene pyrimidine dimers 
(CPDs) and 6-4 photoproducts or 
pyrimidine-pyramidone (6-4). Exposure 
to UVA causes DNA damage through the 
formation of unstable reactive oxygen 
species (ROS) and cyclobutene mono 
adducts, especially when it is combined 
with psoralen. DNA synthesis and repair 
mechanisms are also impaired due to 
UV exposure through the upregulation 
pathway of p53 gene expression.6
Effects of phototherapy on T cells
UV exposure activates regulatory 
T cells and increases the production of 
anti-inflammatory cytokines, such as 
interleukin-10 (IL-10) and tumor necrosis 
factor-α (TNF-α).6 UV converts the trans- 
to cis- urocanic acid (UCA) isomer which 
upregulates the expression of genes 
contributing to apoptosis, cell cycle 
termination, and formation of oxidative 
stress.5 cis-UCA also binds to serotonin-
2A receptors, causing suppression of 
the immune system by converting the 
cytokines of T-helper (Th)1 to Th2 cells.7 
UV diminishes the interaction between 
APCs and T cells. One of the APCs, CD103- 
dendritic cells, produces retinoic acid 
and induces activation of regulatory T 
cells following UV exposure.8
Effects of phototherapy on mast cells
UV does not have much impact on 
the number of mast cells in the dermis, 
however, it suppresses their function. 
PUVA increases the stability of the mast 
cell membrane, reducing the release 
of histamine and other inflammatory 
mediators. In chronic UVA1 exposure 
mast cell apoptosis occurs, causing 
significant decrease in their number.9 
Effects of phototherapy on keratinocytes
Keratinocytes release immunosuppressive 
cytokines, such as IL-6, -8, -10, -12, -15, 
granulocyte-macrophage colony-
stimulating factor (GMCSF), and 
prostaglandins following UV exposure. 
These cytokines inhibit the expression 
of co-stimulatory molecules on APCs 
surface, decreasing their function and 
inhibiting T cells activation.6 An acute 
inflammatory response manifested as 
sunburn occurs due to UV penetration, 
especially UVB in the epidermis and 
superficial dermis. Sunburn triggers the 
release of prostaglandins, leukotrienes, 
histamine, IL-1, and TNF-α, resulting in 
pain. Nitric oxide causes erythema on the 
skin that persists for 24 hours and fades 
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within two to three days, followed by 
desquamation and pigmentation of the 
skin. Cells with frequent DNA synthesis 
phases are more susceptible to apoptosis 
by UV radiation. Therefore, keratinocytes 
are riskier than melanocytes.10
Effect of phototherapy on melanocytes
When melanocytes are exposed 
to UV, pituitary gland releases 
α-melanocyte-stimulating hormone 
(α-MSH) and adrenocorticotropic 
hormone (ACTH). These hormones 
stimulate melanocortin 1 receptors on 
the surface of melanocytes, leading to 
melanogenesis and redistribution of 
melanocytes, manifested as tanning.10 
NB-UVB induces proliferation and 
migration of melanocytes from their 
reservoir, the outer sheath of hair roots, 
to the epidermis. It also upregulates 
tyrosinase to increase melanin synthesis 
by melanocytes. This is the relevance of 
phototherapy in vitiligo.11
Effects of phototherapy on collagen
UV inhibits collagen synthesis 
and increases collagenase production. 
UVA plays a greater role because of its 
deeper penetration. PUVA suppresses 
collagen formation and triggers matrix 
metalloproteinase-I (MMP-1) synthesis 
from dermal fibroblasts via protein 
kinase pathway and induction of IL-1 
and IL-6. MMP-1 is the main protease 
for degradation of type I and III collagen 
into small fragments. UVB decreases 
the amount of collagen indirectly by 
triggering keratinocytes to release  IL-
1, IL-6, and TNF-α, which eventually 
stimulating fibroblasts to produce MMP-
1.12
Side Effects of Phototherapy
Photoaging
UV triggers skin photoaging 
which manifested as deep wrinkles, 
loss of elasticity, rough and dullness, 
uneven color, impaired wound healing, 
formation of purpura and telangiectasia, 
and growth of benign or malignant 
masses.13 Histologically, photoaging is 
characterized by increasing elastosis 
and collagen fragmentation at the 
dermo-epidermal junction with 
irregular thickness of epidermis and 
areas of atrophy and acanthosis. There 
is an increasing number of hyperplastic 
fibroblasts and inflammatory cells 
including mast cells, eosinophils, 
and mononuclear cells in the dermis. 
Melanocytes also increase to protect the 
skin against UV.14EMBASE, UpToDate, and 
the Cochrane Library was conducted. 
Articles were limited to those relating 
to photoaging. There are two major 
approaches in the current management 
of photoaging. This includes strategies to 
prevent against ultraviolet damage (e.g. 
sunscreen
Carcinogenesis
Chronic and excessive exposure to 
UV is the major risk factor for developing 
melanoma and non-melanoma skin 
cancer (NMSC).15 Under normal 
circumstances, nucleotide excision 
repair (NER) and base excision repair 
(BER) protect DNA damage. If these 
systems failed, DNA mutation occurs.16 
Most DNA mutations do not have a major 
impact because the majority of genomes 
are not used in the transcription process. 
However, if mutations occurred in 
oncogenes and/or tumor suppressor 
genes, it results in malignancies .10 UV-
induced immunosuppression is another 
factor to prevent the eradication of 
immunogenic tumor cells.16
A retrospective study of 60,321 
patients found that NB-UVB was not 
associated with skin cancer in vitiligo 
patients, even if the patient had more 
than 500 phototherapy sessions.17 
Another retrospective study also found 
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similar results, the incidence of NMSC in 
patients receiving whole body NB-UVB 
was not significantly different compared 
to the general population.18 However, 
The PUVA Follow-up Study observed 
1,380 psoriasis patients prospectively 
with a mean follow-up time of 20.2 years. 
The incidence of melanoma increases 15 
years after the first exposure to PUVA, 
especially in the patient with more than 
200 sessions.19 A 30-year prospective 
study found that patients with more 
than 350 PUVA sessions had a 30 times 
higher risk of developing squamous 
cell carcinoma (SCC) than the general 
population, while the risk of developing 
basal cell carcinoma (BCC) was only five 
times higher.20 Until now, there is no 
large-scale study related to the risk of 
skin cancer in UVA1. Two publications 
are reporting the incidence of skin cancer 
in patients receiving UVA1, however, the 
causality has not been proven .21 NB-UVB 
is preferred over PUVA because of its 
good safety profile.22
Phototherapy in Various Dermatoses
Atopic dermatitis (level of evidence/LoE 
II)
Atopic dermatitis (AD) is a chronic 
inflammatory skin disease characterized 
by recurring pruritus, usually beginning 
in infancy or childhood.24,25 Phototherapy 
reduces the inflammatory response 
and improves skin barrier function, 
thereby preventing the penetration of 
allergens and irritants.26 NB-UVB also 
has an antibacterial activity to prevent 
Staphylococcus aureus infection which is 
often found in AD.27  In 2010, the American 
Academy of Dermatology (AAD) 
published guidelines for phototherapy 
in AD. The dose is adjusted based on 
skin type or the minimal erythema dose 
(MED) and must be monitored by expert 
physicians. Phototherapy can be used 
alone or in combination with topical 
moisturizers and corticosteroids.28 
TABLE 1. Guideline for narrowband ultraviolet B (NB-UVB) and psoralen ultraviolet 
A (PUVA) phototherapy in atopic dermatitis according to the American 
Academy of Dermatology in 2010*
Skin
types
NB-UVB (mJ/cm2) Dose UVA (J/cm2) Dose
Initial Increasing dose every session Maximum Initial Increasing dose 
every session
Maximum 
I 130 15 2000 0.5 0.5 8
II 220 25 2000 1.0 0.5 8
III 260 40 3000 1.5 1.0 12
IV 330 45 3000 2.0 1.0 12
V 350 60 5000 2.5 1.5 20
VI 400 65 5000 3.0 1.5 20
The initial dose of UVB 50% minimal erythema dose
Session 1 - 20 Increasing 10% from minimal erythema dose
Session ≥21 Increasement based on physician’s consideration
If the patient does not undergo phototherapy for:
4 - 7 days Maintained dose
1 - 2 weeks Decreased 25%
2 - 3 weeks Decreased 50% or started from initial dose
3 - 4 weeks Started from the initial dose
Phototherapy is given 3-5 times per week. A minimal erythema dose (MED) measurement is 
recommended because of the large MED range of NB-UVB based on skin type. The phototherapy unit 
should be calibrated once per week because the power of the UVB lamp decreases over time.
*Cited from original reference No. 28
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NB-UVB is an effective, safe, and 
most widely used phototherapy modality 
for AD. A prospective study involving 
30 children with moderate to severe 
AD showed a significant reduction in 
Scoring Atopic Dermatitis (SCORAD) 
after receiving twice-weekly NB-UVB 
for 12 weeks.29 NB-UVB and medium-
dose (MD-UVA1) have similar effectivity 
in reducing signs and symptoms of AD. 
PUVA and BB-UVB are not recommended 
for AD because of the risk of malignancy 
and low efficacy, respectively.30 NB-UVB 
alone is as effective as the combination 
of NB-UVB and UVA.31 
Chronic hand dermatitis (LoE II)
Chronic hand dermatitis is an 
inflammatory dermatosis characterized 
by erythema, desquamation, fissures, 
swelling, and vesicle formation 
with pain, itching, and burning in 
the hands.32 Severe chronic hand 
dermatitis is often resistant to topical 
corticosteroid treatment. Data from UK 
large-scale survey found the majority 
of dermatologists use PUVA for the 
treatment of chronic hand dermatitis.33
An RCT of 60 subjects compared the 
effectiveness of topical PUVA with local 
NB-UVB for hand dermatitis unresponsive 
to ultra-potent corticosteroids. The 
control group received topical PUVA 
twice per week for 12 weeks with an 
initial UVA dose of 0.5 J/cm2 which was 
increased to a maximum dose of 6 J/
cm2. The intervention group received 
localized NB-UVB twice weekly for 12 
weeks with an initial UVB dose of 0.5 J/
cm2 which was increased to a maximum 
dose of 10 J/cm2. The result showed both 
PUVA and NB-UVB are safe and effective 
for chronic hand dermatitis, although 
erythema was higher in the intervention 
group.32 Another clinical trial indicated 
that there were no significant differences 
between the effectiveness of topical 
PUVA and localized NB-UVB in for 
chronic hand eczema.34
Polymorphic light eruption (LoE II)
Polymorphic light eruption (PMLE) 
is triggered by ultraviolet exposure or 
visible light. The clinical features of 
PMLE are vesico-papular, vesico-bulous, 
erythematous-edematous eruptions, 
resembling erythema multiforme or 
insect bites, and urticaria in areas of 
the body that are frequently exposed 
by sunlight, such as the neck, arms, and 
back of the hands.35 Phototherapy is used 
as a second-line treatment for PMLE 
because of the “skin hardening” effect 
through the thickening of the stratum 
corneum, hyperpigmentation, epidermal 
hyperplasia, and immunosuppression. 
In PMLE, the initial dose of NB-UVB is 
determined based on skin type or MED. 
NB-UVB is given two to three times 
per week for a total of 15 sessions. If a 
photosensitivity reaction occurs, the 
patient is given prednisone 0.6 - 0.8 mg/
kg for seven to 10 days. After completion, 
patients are advised to sunbathe for 
20 to 30 minutes per week without 
sunscreen to maintain desensitization 
of the skin. PUVA is recommended if 
recurrence occurs after NB-UVB.36 A case 
series demonstrated the effectiveness of 
NB-UVB in 91% of PMLE patients who 
received at least 15 sessions of therapy.37 
PUVA can be given at an initial dose of 
1.5 J/cm2 three times per week with 
20% increase in subsequent sessions 
for four to eight weeks.38 The results of 
a clinical trial in 25 patients showed the 
effectiveness of NB-UVB was similar to 
PUVA for PMLE.39
Chronic urticaria (LoE II)
Chronic urticaria may be 
accompanied by angioedema which 
lasting more than 6 weeks with 
J Med Sci, Volume 53, Number 4, 2021 October:
individual lesions lasting less than 24 
hours. Mast cells play a role in urticaria. 
Phototherapy increases the stability of 
the mast cell membrane, thus reducing 
the release of histamine and other 
inflammatory mediators.40
Clinical trial in 24 patients with 
chronic urticaria found either PUVA 
or NB-UVB three times per week for 20 
sessions with the initial dose based on the 
patient’s skin type showed a significant 
decrease in the total severity score 
(TSS) of urticaria after phototherapy 
(p<0.05) without significant differences 
between the two groups in terms of 
symptom improvement and urticaria 
TSS reduction (p>0.05). However, 
gastrointestinal complaints were higher 
in the PUVA group.40 Another clinical 
trial assessed the effectiveness of NB-
UVB and loratadine combination therapy 
versus loratadine monotherapy using an 
urticaria activity score (UAS). The mean 
UAS was lower after 8 and 16 sessions 
in the intervention group compared to 
control (p<0.01). It concluded that NB-
UVB could be used as an adjunct therapy 
in chronic urticaria.41
Chronic pruritus (LoE II)
The etiology of chronic pruritus is 
unknown in more than 20% of patients, 
however, primary biliary cirrhosis and 
chronic kidney disease are associated 
with chronic pruritus.43 Phototherapy is 
thought to reduce the production of IL-
17, -23, -4, and -3 which inducing itch. 
UV also affects nerve signals through the 
endogenous opioid system and reduces 
the density of nerve fibers in the skin.44 
A clinical trial in 30 patients with uremic 
pruritus found that 15 sessions of NB-
UVB significantly decreased the symptom 
compared to oral cetirizine and topical 
liquid paraffin (p=0.001).45 However, 
recent guidelines from the European 
Association of the Study of Liver Disease 
and American Association for the Study 
of Liver Disease do not address the role 
of UVB for chronic pruritus due to limited 
evidence.44
Lichen planus (LoE II)
Lichen planus is a chronic 
mucocutaneous and nail inflammatory 
disease characterized by itchy, 
polygonal, purple flat papules with 
unknown etiology. It is suspected that 
the cellular immune system plays 
a role in the destruction of basal 
keratinocytes. The role of phototherapy 
on lichen planus is not fully understood, 
however, it is thought to affect T cell 
apoptosis, anti-inflammatory effects, 
and immunosuppression. Phototherapy 
can be used for both generalized and 
localized lichen planus.46,47
A clinical trial in 46 subjects found 
that NB-UVB given thrice weekly for six 
weeks was superior to prednisolone 0.3 
mg/kg for the same period (p=0.008). 
Moreover, patient satisfaction was higher 
with phototherapy (p=0.012).47 Case 
series in 10 patients with generalized 
lichen planus showed a complete 
response in 80% of patients who received 
NB-UVB thrice weekly. However, the 
recurrence rate in three to six months 
after completed phototherapy was high, 
ranging from 10-37.5%.48 A case report 
in a pediatric patient with lichen planus 
pigmentosus-inversus refractory to 
topical corticosteroids exhibited a good 
response following localized NB-UVB 
twice weekly at an initial dose of 50 mJ/
cm2 for 30 sessions.49
Scleroderma (LoE II)
Scleroderma is a chronic 
autoimmune disease with involvement 
of the skin, joints, and internal organs. 
The clinical features of scleroderma 
include the thickening and elasticity 
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of the skin. There are two types of 
scleroderma, namely systemic and 
localized. Localized scleroderma has 
a better prognosis because there is no 
internal organ involvement. UVA and 
UVB are often used in the management 
of localized scleroderma.12
UVA increases the expression of the 
MMP-1 gene and decreases the levels of 
collagen I and III and TGF-β. In addition, 
the effect of UVA on increasing vascular 
endothelial growth factor (VEGF) and 
decreasing apoptosis of endothelial cells 
also results in a reduction of sclerosis in 
the dermis.50 Although PUVA is effective 
with the mean cumulative dose of fewer 
than 400 J/cm2, the use of psoralen is 
associated with increased side effects 
and discomfort for patients. Thus PUVA 
is not recommended for the management 
of scleroderma.51 UVB increases the 
synthesis of α-MSH receptors on 
keratinocytes and melanocytes. α-MSH 
is an antifibrotic mediator that works 
by increasing the expression of MMP-1 
mRNA.52
A systematic review of 62 pediatric 
and adult with active morphea showed 
that MD-UVA1 (50 J/cm2), low dose-UVA1 
(LD-UVA1) (20 J/cm2), and NB-UVB five 
times a week for eight weeks has the 
same effectiveness.53 Case reports of 
three patients with localized scleroderma 
who received UVA1 with a total dose of 
540-1800 J/cm2 showed improvement of 
collagen fibers texture with reducing of 
their size.54 The Single Hub and Access 
Point for Pediatric Rheumatology in 
Europe (SHARE) recommends MD-UVA1 
in children with localized scleroderma 
due to its effectiveness in improving 
tenderness and reducing skin thickness.55
Cutaneous T cell lymphoma (LoE II)
Cutaneous T cell lymphoma (CTCL) 
is a rare neoplasm of T cells in the skin. 
Mycosis fungoides (MF) is the most 
common type, occurring in more than 
50% of all CTCL. The classic feature 
of MF is erythematous patches which 
eventually developing into plaques, 
tumors, and erythroderma.56 Another 
type is Sezary syndrome (SS), manifested 
as erythroderma and the presence 
of circulating atypical T cells with or 
without lymphadenopathy.57 MF is 
effectively treated using phototherapy.58 
NB-UVB and PUVA induce lymphocytes 
and keratinocytes apoptosis, decrease 
Langerhans cells proliferation, and 
suppress pro-inflammatory cytokine 
production. UVA, with its deeper 
penetration, induces faster lymphocytes 
apoptosis (12 hours after radiation), 
inhibits inflammation by modulating 
pro-inflammatory cytokines via 
phosphatidylinositol 3-kinase (PI3K) 
pathway.58 
The  results of the meta-analysis 
in 778 early-stage MF patients showed 
a superior response to PUVA (90.9%) 
compared to NB-UVB (87.6%), without 
the difference of side effects.59  Median 
relapse of early-stage MF in patients 
receiving  PUVA was longer than 
that in NB-UVB (p-value <0.0001).60 A 
comparative study of 43 MF patients 
showed that patients receiving PUVA 
or NB-UVB had a longer median 
progression from patch and plaque 
stage to tumor stage as well as life 
expectancy compared to patients who 
did not receive phototherapy.61 In 2015, 
the American Academy of Dermatology 
published phototherapy guidelines for 
MF. The dose of 8-methoxy psoralen (8-
MOP) is 0.6 mg/kg with UVA exposure 2 
hours thereafter. The frequency of PUVA 
is twice weekly with the initial dose is 
determined based on the patient’s skin 
type.62
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TABLE 2. Guideline for narrowband ultraviolet B (NB-UVB) and psoralen ultraviolet 
A (PUVA) phototherapy in mycosis fungoides according to the American 
Academy of Dermatology in 2015.*
Skin
types
NB-UVB (mJ/cm2) Dose UVA (J/cm2) Dose
Initial Increasing dose every session Initial
Increasing dose every 
session
I 130 15 0.5 0.5
II 220 25 1.0 0.5
III 260 40 1.5 1.0
IV 330 45 2.0 1.0
V 350 60 2.5 1.5
VI 400 65 3.0 1.5
If the patient does not 
undergo phototherapy for:
NB-UVB PUVA
4 - 7 days Maintained dose Maintained dose
1 - 2 weeks Decreased 25% Decreased 25%
2 - 3 weeks Decreased 50% Decreased 50%
3 - 4 weeks Started from the initial dose Decreased 75%
>4 weeks Started from the initial dose Started from the initial 
dose
If no response occurs after 20 treatments, the dose of NB-UVB can be increased by 50 to 
100 mJ/cm2, in PUVA the dose can be increased by 0.5 to 1 j/cm2.
*Cited from original reference No. 62
Pityriasis lichenoides (LoE III)
Pityriasis lichenoides (PL) is a 
papulosquamous dermatosis with 
unknown etiology. The clinical picture 
of acute PL is generalized papule with 
necrosis and scar formation, while the 
chronic condition is characterized by 
erythematous macula with scales that 
recur periodically. The PL spectrum 
consisted of pityriasis lichenoides et 
varioliformis acuta (PLEVA), febrile 
ulceronecrotic Mucha Habermann 
disease (FUMHD), and pityriasis 
lichenoides chronica (PLC). First-line 
therapy is topical corticosteroids; oral 
antibiotics (tetracycline, erythromycin, 
and azithromycin); and phototherapy.63 
Phototherapy modulates the immune 
response, thereby repairing PL lesions.64 
A systematic review of 309 PL 
patients who received one of the BB-UVB, 
NB-UVB, or PUVA showed a complete 
response in 91%, 75%, and 69% of cases, 
respectively, whereas partial responses 
occurred in 0%, 20.6%, and 22% of 
cases, respectively. The recurrency after 
completing phototherapy was 25.7%.65 A 
prospective study in Vietnam involving 
29 PLC patients showed 82% complete 
response to NB-UVB (cumulative dose 
of 9,760.5 mJ/cm2 over 4.6 weeks period) 
without recurrence after three months.66 
A systematic review demonstrated 
the effectiveness of phototherapy in 
64 pediatric patients with a complete 
response was as followed: 89.6% in BB-
UVB with recurrence of 23.1%, 73% in 
NB-UVB without recurrence, and 83% 
in PUVA with a high recurrence rate of 
60%.64
Other Dermatoses
Phototherapy is also effective 
for other dermatoses, such as graft-
versus-host disease (GVHD), granuloma 
annulare, systemic mastocytosis, 
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lymphomatoid papulosis, perforating 
dermatosis, and pityriasis rubra pilaris 
(PRP). However, the evidence are limited 
to retrospective studies or case reports 
(LoE IV), thus there are no phototherapy 
guidelines for these dermatoses.67-72
CONCLUSION 
Besides psoriasis and vitiligo, 
phototherapy can be used for the 
management of various dermatoses 
either as a single or combination 
therapy. Strong scientific evidence 
shows that phototherapy is effective 
in the management of AD, CTCL, 
scleroderma, chronic hand dermatitis, 
chronic urticaria, lichen planus, chronic 
urticaria, photodermatosis, and chronic 
pruritus. However, phototherapy has 
side effects such as photoaging, risk of 
carcinogenesis, and photosensitivity 
reactions, thus the physicians have 
to take consideration while utilizing 
this modality. Until now, research in 
phototherapy is still being carried out 
to determine the therapeutic effect and 
the most appropriate dose for various 
dermatoses.
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